Program Overview:
The joint providership of University of Cincinnati College of Medicine and Focus Medical Communications, in collaboration with Chronic Liver Disease Foundation, Gi Health Foundation, and Gastroenterology & Hepatology Advanced Practice Providers presents the New England GI & Liver Update 2025. The initiative will provide an educational update on key areas of GI and hepatology in the New England region.

Target Audience
This activity has been designed to meet the educational needs of healthcare providers, including gastroenterologists, hepatologists and advanced practice providers involved in the care of patients with gastroenterology and hepatology diseases.

​

Learning Objectives

• Integrate current evidence and guidelines for the diagnosis, risk stratification, and comprehensive management of a broad spectrum of acute and chronic liver diseases.

• Develop evidence-based strategies for managing advanced liver disease complications

• Critically appraise emerging therapeutic options and treatment paradigms

• Apply recent clinical trial data, technological innovations, and updated guidelines to optimize clinical practice and patient outcomes in gastroenterology and hepatology.
  ​

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Focus Medical Communications. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

 

The University of Cincinnati designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

​

MOC Designation:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

​

Disclosure of Relevant Financial Relationships:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

 

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

All relevant relationships have been mitigated prior to the commencement of this activity.

​

All additional planning committee members, the University of Cincinnati staff, and Focus Medical Communications staff have no relationships to disclose.

​

Planning Committee:

 

Course Directors:

• Fredric Gordon, MD

  • Speakers Bureau: Gilead​

• Braden Kuo, MD, MSc

  • Consulting: ATMO, Phathom, Cindome,Ironwood​

  • Research: ATMO, Takeda, Ironwood

• Kenneth Sherman, MD, PhD

  • Site Investigator: AbbVie, Gilead, Helio, Zydus​

  • Consultant: CinRx, PureTech

  • Delphi Panel Member: GSK

  • DSMB: Horizon/Amgen, Pilant, MedPace

• Kyle Staller, MD, MPH

  • Consultant: Mahana, Salix, Laborie, Gemelli, ​
    Ardelyx, Ferring​

  • Expert Witness: Takeda

 

Disclaimer:

The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

 

Off-Label Disclosure Statement:

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

 

Fee Information:

MD/DO/PhD $100; NP/PA/RN/PharmD/Other $75; Fellow $0; Industry $500.​​​